vimarsana.com
Home
Live Updates
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer : comparemela.com
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that
Related Keywords
United States ,
Rhui Zhou ,
Guangdong ,
China ,
Thailand ,
Macau ,
Taiwan ,
Japan ,
Hong Kong ,
Suzhou ,
Jiangsu ,
Sanofi Incyte ,
Eli Lilly ,
Innovent Biologics Inc ,
Md Anderson Cancer Center ,
China National Medical Products Administration ,
Linkedin ,
Incyte Corporation ,
Innovent Biologics ,
Drug Evaluation ,
National Medical Products Administration ,
Breakthrough Therapy Designation ,
Senior Vice President ,
Therapy Designation ,
Mainland China ,
Adv Med ,
Thailand Business ,
comparemela.com © 2020. All Rights Reserved.